Opening book details…
Can I read Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study on EtoBox?
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study by Hans Gelderblom; Robin L. Jones; Suzanne George; Claudia Valverde Morales; Charlotte Benson; Jean-Yves Blay; Daniel J. Renouf; Toshihiko Doi; Axel Le Cesne; Michael Leahy; Sabine Hertle; Paola Aimone; Ulrike Brandt; Patrick Schӧffski is a Medicine article available to read on EtoBox.
What is Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study about?
## Background The majority of patients with advanced gastrointestinal stromal tumours (GISTs) develop resistance to imatinib and sunitinib, the standard of care for these patients. This study evaluated the combination of buparlisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, with imatinib in patients with advanced GIST, who have failed prior therapy with imatinib and sunitinib. ## Methods This Phase 1b, multicentre, open-label study aimed to determine the maximum tolerated dose (MTD) and/or a recommended Phase 2 dose of buparlisib in combination with 400 mg of imatinib through a dose-escalation part and a dose-expansion part, and also evaluated the clinical profile of the combination. ## Results Sixty patients were enrolled, including 25 in the dose-escalation part and 35 in the dose-expansion part. In the combination, MTD of buparlisib was established as 80 mg. No partial or complete responses were observed. The estimated median progression-free survival was 3.5 months in the expansion phase. Overall, 98.3% of patients had treatment-related adverse events (AEs), including 45% with grade 3 or 4 AEs. ## Conclusions Buparlisib in combination with imatinib provided no additio
Who reads Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Hans Gelderblom; Robin L. Jones; Suzanne George; Claudia Valverde Morales; Charlotte Benson; Jean-Yves Blay; Daniel J. Renouf; Toshihiko Doi; Axel Le Cesne; Michael Leahy; Sabine Hertle; Paola Aimone; Ulrike Brandt; Patrick Schӧffski
- Publisher
- Nature Publishing Group; Springer Science and Business Media LLC; Society for Mining, Metallurgy and Exploration Inc. (ISSN 0007-0920)
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)